Shots:

• Innovent and Eli Lilly entered into a licensing agreement to develop & commercialize novel diabetic therapy- OXM3 in China
• The license agreement will strengthen Innovent’s diabetic portfolio with the addition of Eli Lilly’s mid-clinical stage metabolic disease asset- OXM3
• OXM3 is an oxyntomodulin analog- binds to & activates GLP-1 and the glucagon receptor demonstrating wt. loss and improvement in glycemic control in its early clinical studies and has the potential to be developed for diabetes- obesity and NASH

Click here to­ read full press release/ article

Ref: Innovent | Image: Eli Lilly